Citadel Advisors’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Citadel Advisors’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-59,200	Closed	-$10.2M	–	9483
2015 Q1	$10.2M	Sell	59,200 -19,200	-24%	-$2.82M	0.01%	1431
2014 Q4	$9.01M	Sell	78,400 -16,400	-17%	-$1.99M	0.01%	1478
2014 Q3	$14.8M	Buy	94,800 +26,600	+39%	+$3.86M	0.02%	1092
2014 Q2	$8.41M	Buy	68,200 +43,400	+175%	+$4.8M	0.01%	1401
2014 Q1	$2.57M	Buy	24,800 +10,100	+69%	+$1.03M	﹤0.01%	2398
2013 Q4	$1.32M	Buy	14,700 +3,200	+28%	+$255K	﹤0.01%	2940
2013 Q3	$769K	Buy	11,500 +1,600	+16%	+$110K	﹤0.01%	3369
2013 Q2	$655K	Buy	+9,900	New	+$566K	﹤0.01%	3582

Other funds holding SLXP

MMG

Monetary Management Group St Louis, Missouri $419M AUM 29.55% 1-Year Est. Return

Citadel Advisors's SLXP Position: Q2 2015 in Review

Citadel Advisors sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q2 2015, closing a stake of 14,386 shares — an estimated $2.49M sold.

Citadel Advisors first reported a position in SLXP in Q2 2013 and held it in 8 quarters. The position peaked at $154M in Q3 2014. 1 fund tracked by Wall St. Rank holds SLXP as of Q2 2015.

Citadel Advisors reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q2 2015 after selling out during the quarter.
Citadel Advisors sold 14,386 SALIX PHARMACEUTICALS LTD DEL shares in Q2 2015, an estimated $2.49M.
Citadel Advisors first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 8 quarters.
Citadel Advisors's SALIX PHARMACEUTICALS LTD DEL position peaked at $154M in Q3 2014.
1 fund tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q2 2015.

Based on Citadel Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.